The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL).
Elias Jabbour
Consultant or Advisory Role - Pfizer
Susan Mary O'Brien
No relevant relationships to disclose
Deborah A. Thomas
Consultant or Advisory Role - Pfizer
Jeffrey L. Jorgensen
No relevant relationships to disclose
Partow Kebriaei
No relevant relationships to disclose
Michael E. Rytting
No relevant relationships to disclose
Sergernne York
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Monica Kwari
No relevant relationships to disclose
Stefan Faderl
No relevant relationships to disclose
Mary Beth Rios
No relevant relationships to disclose
Jorge E. Cortes
Honoraria - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis
Luis Fayad
No relevant relationships to disclose
Robert Tarnai
No relevant relationships to disclose
Sa Wang
No relevant relationships to disclose
Richard E. Champlin
No relevant relationships to disclose
Anjali S. Advani
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Hagop Kantarjian
Research Funding - Pfizer